bioRxivNeurosciencePreprint
Acetylation of lysine 82 initiates TDP-43 nuclear loss of function by disrupting its nuclear import
Sitao ZhangiD, Sonia Vazquez‐SancheziD, Shan LuiD, Michael W. BaughniD, Jaisen Lim, Spencer Oung, Lilian Gao, Jolene K. DiedrichiD, John R. YatesiD, Haiyang Yu, John RavitsiD, Don W. ClevelandiD
Abstract
The hallmark of a spectrum of age-dependent neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), is a TDP-43 proteinopathy that includes nuclear loss of function and cytoplasmic aggregation. Here, reduced proteasome activity, as naturally occurs during aging, is shown to inhibit nuclear import of TDP-43. Quantitative mass spectrometry is used to determine that TDP-43 is the protein whose nuclear localization is most perturbed upon reduction in proteasome activity, culminating in elevated cytoplasmic TDP-43. Interaction of importin-1 with the bipartite classical nuclear localization sequence (cNLS) of TDP-43 is shown to be disrupted by partial proteasome inhibition but maintained by replacement with a PY-NLS that is recognized by importin-{beta}2. Mechanistically, this nuclear depletion of TDP-43 is shown to be driven by ubiquitination or acetylation of lysines 79, 82, and 84 within the cNLS when proteasome activity is reduced in human neurons. Specifically, acetylation at lysine 82 is sufficient to abolish TDP-43 binding to importin-1 and subsequent nuclear import of TDP-43. Moreover, using acetylation-specific TDP-43 antibodies, we detected acetylation of lysine 82 in the motor cortex of sporadic ALS patients but not control subjects. Our findings demonstrate that post-translational acetylation at lysine 82 of TDP-43 drives disruption of its importin-1-mediated nuclear import and is sufficient to initiate TDP-43 nuclear loss of function and cytoplasmic accumulation, evidence supporting acetylation as a plausible initiator of TDP-43 proteinopathies.
- organism: human
- assay: proteomics
- research focus: differential expression
- research focus: protein structure prediction
- research focus: protein design
- research focus: drug response / drug discovery
- approach: statistical model
- approach: experimental assay
- Citations
- 10
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Ubiquitin Proteasome System Components, RAD23A and USP13, Modulate TDP-43 Solubility and Neuronal Toxicity
Casey Dalton, Jelena Mojsilovic‐Petrovic, … Robert Gordon Kalb·Journal of NeurosciencePeer-reviewed·Dec 10, 2025
- TBK1 eliminates aggregation-prone monomeric TDP-43 through the IFNβ-immunoproteasome pathway
Shohei Sakai, Kotaro Oiwa, … Koji Yamanaka·bioRxiv·Apr 29, 2025
- Loss of TBK1 activity leads to TDP-43 proteinopathy through lysosomal dysfunction in human motor neurons
Jin Hao, Michael F. Wells, … Kevin C. Eggan·bioRxiv·Oct 11, 2021
- Nemo-like kinase disrupts nuclear import and drives TDP43 mislocalization in ALS
Michael E. Bekier, Emile S. Pinarbasi, … Sami J. Barmada·Journal of Clinical InvestigationPeer-reviewed·Jun 24, 2025
- Sirtuin-1 Sensitive Lysine-136 Acetylation Drives Phase Separation and Pathological Aggregation of TDP-43
J. Garcia Morato, F. Hans, … P. J. Kahle·bioRxiv·May 26, 2020
- Reduction of Nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43-related neurodegeneration
Leon Tejwani, Youngseob Jung, … Janghoo Lim·Journal of Clinical InvestigationPeer-reviewed·Jun 29, 2023